Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 812 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Scope of the Report:
This report focuses on the Rivaroxaban in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
- North America (USA, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America, Middle East and Africa
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Acute coronary syndrome (ACS)
- Venous thromboembolism (VTE)
There are 13 Chapters to deeply display the global Rivaroxaban market.
Chapter 1, to describe Rivaroxaban Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Rivaroxaban , with sales, revenue, and price of Rivaroxaban , in 2015 and 2016;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Rivaroxaban , for each region, from 2011 to 2016;
Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;
Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;
Chapter 11, Rivaroxaban market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;
Chapter 12 and 13, to describe Rivaroxaban sales channel, distributors, traders, dealers, appendix and data source.